Literature DB >> 2799303

Methotrexate treatment of rheumatoid arthritis: effects on radiological progression.

S Reykdal1, K Steinsson, K Sigurjónsson, A Brekkan.   

Abstract

Radiological progression was evaluated in 15 patients with rheumatoid arthritis (RA) treated with methotrexate (MTX). Prior to MTX treatment, all the patients had failed on other slow-acting agents and all showed radiological deterioration. For each patient, three sets of radiographs of hands and wrists were evaluated: prior to MTX treatment while on other slow-acting agents, at the beginning of MTX treatment, and at the most recent evaluation on MTX. Two experienced radiologists evaluated the radiographs independently. The rate of radiological progression was calculated by dividing the change in radiological score by the number of months between sets of radiographs. The mean time from film set one to two (period one) was 29.4 months and from set two to three (period two) 32.5 months. The mean rate of radiological progression for period one was 0.576 and for period two, 0.381. Eight patients showed decline in radiological progression during MTX treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2799303     DOI: 10.3109/03009748909099932

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  5 in total

1.  Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate.

Authors:  O Sander; G Herborn; E Bock; R Rau
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

Review 2.  [Methotrexate].

Authors:  R Rau
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

Review 3.  A clinical and economic review of disease-modifying antirheumatic drugs.

Authors:  S E Gabriel; D Coyle; L W Moreland
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.

Authors:  Roy Fleischmann; Imran Iqbal; Pallavi Nandeshwar; Andres Quiceno
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Improved radiological outcome of rheumatoid arthritis: the importance of early treatment with methotrexate in the era of biological drugs.

Authors:  Christoph Fiehn; Elisabeth Belke-Voss; Dietmar Krause; Siegfried Wassenberg; Rolf Rau
Journal:  Clin Rheumatol       Date:  2013-08-08       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.